<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38628706</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Assessment of lung function variability documents airflow limitation in many patients with long covid.</ArticleTitle><Pagination><StartPage>e29261</StartPage><MedlinePgn>e29261</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e29261</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e29261</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">It is estimated that 65 million people worldwide suffer from long covid (LC). Many LC symptoms are also reported by patients with airflow limitation, used to confirm asthma. The primary aim was to detect airflow limitation in LC patients by a methacholine bronchial provocation test (BPT) and if negative, by evaluation of diurnal variability in forced expiratory flow in 1 second (FEV<sub>1</sub>) over a two-weeks' period. The second aim was to assess responsiveness to asthma treatment on diurnal FEV<sub>1</sub> variability and LC symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Patients with LC for at least six months were recruited in this open diagnostic study. Burden of LC symptoms were reported on a 10-point Likert scale (0&#xa0;=&#xa0;not troubled, 10&#xa0;=&#xa0;extremely troubled) at inclusion and after three weeks' asthma treatment. A positive methacholine BPT was defined by an accumulated provocation dose (PD<sub>20</sub>)&lt;8 &#x3bc;mol causing 20% fall in FEV<sub>1</sub>. App-based spirometer was used for diurnal FEV<sub>1</sub> variability, deemed positive by diurnalvariability in FEV<sub>1</sub> &#x2265;12%.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Airflow limitation was documented by positive methacholine BPT in 8/30 (27%), or by excessive diurnal variability in FEV<sub>1</sub> in 21/22 (95%) of the BPT negative LC patients. One patient dropped out due to personal issues. Three weeks' asthma treatment normalised mean diurnal FEV<sub>1</sub> variability from 18.0% to 7.3%, p&#xa0;&lt;&#xa0;0.001. Significant reductions were observed for fatigue and dyspnoea, from 8.3 to 6.1, p&#xa0;&lt;&#xa0;0.001, and 3.0 to 0, p&#xa0;&lt;&#xa0;0.001, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study indicate that airflow limitation may be detected in many LC patients if evaluation of diurnal variability in FEV<sub>1</sub> is included in the diagnostics.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reier-Nilsen</LastName><ForeName>Tonje</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Norwegian Sports Medicine Centre - Football Association, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Norwegian Olympic Sports Centre, Norwegian Olympic and Paralympic Committee and Confederation of Sports, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xf8;nneberg</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Norwegian Sports Medicine Centre - Football Association, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf8;ine</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Norwegian Sports Medicine Centre - Football Association, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordlund</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Astrid Lindgren Children's Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">App-based spirometry</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">Lung function variability</Keyword><Keyword MajorTopicYN="N">Postviral asthma</Keyword></KeywordList><CoiStatement>Tonje Reier-Nilsen is employed as part-time consultant in MediTuner. Charlotte Gr&#xf8;nneberg and Stephanie R&#xf8;ine have no conflicts of interest. Bj&#xf6;rn Nordlund was part of founding MediTuner AB, the company owning the medical device AsthmaTuner.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>3</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38628706</ArticleId><ArticleId IdType="pmc">PMC11019201</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e29261</ArticleId><ArticleId IdType="pii">S2405-8440(24)05292-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ballering A.V., et al. Persistence of somatic symptoms after COVID-19 in The Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization W.H.  World Health Organization; 2022. https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition</Citation></Reference><Reference><Citation>Modi P., et al. Clinical profile of 116 patients undergoing post-COVID follow-up - a prospective study. ERJ Open Research. 2021;7(suppl 6):39.</Citation></Reference><Reference><Citation>Davis H.E., et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw. Open. 2021;4(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney L.L., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Reier-Nilsen T., et al. Unsupervised field-based exercise challenge tests to support the detection of exercise-induced lower airway dysfunction in athletes. BMJ Open Sport Exerc Med. 2023;9(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10373716</ArticleId><ArticleId IdType="pubmed">37520311</ArticleId></ArticleIdList></Reference><Reference><Citation>Xepapadaki P., et al. Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J. Allergy Clin. Immunol. 2005;116(2):299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172284</ArticleId><ArticleId IdType="pubmed">16083783</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostransky D., Blais F.X. Postviral bronchial hyperreactivity syndrome: recognizing asthma's great mimic. J. Am. Osteopath. Assoc. 1991;91(5):465&#x2013;468. 471-468.</Citation><ArticleIdList><ArticleId IdType="pubmed">2061102</ArticleId></ArticleIdList></Reference><Reference><Citation>Asthma G.-G.I.f. GINA Main Report. 2023:24&#x2013;25. https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf</Citation></Reference><Reference><Citation>Dempsey J.A., et al. Respiratory influences on sympathetic vasomotor outflow in humans. Respir. Physiol. Neurobiol. 2002;130(1):3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">12380012</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuther D.A. Hypoventilation in asthma and chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 2009;30(3):321&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">19452392</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L., et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am. J. Phys. Med. Rehabil. 2022;101(1):48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovitch N., et al. Reversible peripheral airway obstruction and lung hyperinflation in children presenting with dyspnea and exercise intolerance after COVID-19 infection. J. Allergy Clin. Immunol. Pract. 2022;10(10):2748&#x2013;2749 e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9520121</ArticleId><ArticleId IdType="pubmed">36184531</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusasco V., et al. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur. Respir. J. 2005;26(1):1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">15994380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerg A., et al. Shorter time to clinical decision in work-related asthma using a digital tool. ERJ Open Res. 2020;6(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487349</ArticleId><ArticleId IdType="pubmed">32963995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam G.Y., et al. Exertional intolerance and dyspnea with preserved lung function: an emerging long COVID phenotype? Respir. Res. 2021;22(1):222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343348</ArticleId><ArticleId IdType="pubmed">34362372</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel N., et al. Systemic corticosteroids for management of 'long-COVID': an evaluation after 3 months of treatment. Monaldi Arch. Chest Dis. 2021;92(2)</Citation><ArticleIdList><ArticleId IdType="pubmed">34730322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.H., et al. Corticosteroid outcome may be dependent of duration of use in severe COVID-19. Korean J Intern Med. 2023;38(3):382&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10175872</ArticleId><ArticleId IdType="pubmed">37038264</ArticleId></ArticleIdList></Reference><Reference><Citation>Tichopad A., et al. Adherence to application technique of inhaled corticosteroid in patients with asthma and COVID-19 improves outcomes. BMJ Open Respir Res. 2024;11(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10773384</ArticleId><ArticleId IdType="pubmed">38184317</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesel M., et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst. Rev. 2022;3(3):CD015125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8905579</ArticleId><ArticleId IdType="pubmed">35262185</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankinson J.L., et al. Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test. Eur. Respir. J. 2015;45(5):1283&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4416111</ArticleId><ArticleId IdType="pubmed">25537554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>